EPISODE · Jun 17, 2022 · 16 MIN
MPR Weekly Dose MPR 120 — Child COVID Vaccine Vote; Alopecia Tx Approved; Paxlovid in Standard Risk Patients; Autism Diagnostic Aid; Polyneuropathy hATTR Amyloidosis
from MPR Weekly Dose
FDA panel vote on COVID vaccines for young children; new drug approved to treat alopecia; paxlovid tested in standard risk individuals; a device to aid autism diagnosis; and a new approval for polyneuropathy hATTR.
Embed this episode
Ready to play
MPR Weekly Dose MPR 120 — Child COVID Vaccine Vote; Alopecia Tx Approved; Paxlovid in Standard Risk Patients; Autism Diagnostic Aid; Polyneuropathy hATTR Amyloidosis
0:00
16:15
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 16 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on June 17, 2022.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!